The Western Galilee Hospital, along with the University of Thessaly in Greece, will be leading a study on the efficacy of the RedoxSYS oxidation-reduction potential (ORP) diagnostic system, designed to reduce oxidative stress markers across hypertension, hemodialysis, sepsis, and physical exertion. Ampio Pharmaceuticals, Inc. subsidiary Luoxis is the creator of the RedoxSYS diagnostic system. You can read more about this important partnership here, here and here.
WGH One of Two Hospitals to Spearhead Study
Tags: Ampio, Ampio Pharmaceuticals, Israel, Luoxis, Medical Center, oxidation-reduction, RedoxSYS, Western Galilee Hospital, WGH
- Post published:January 9, 2014
- Post category:GMC Current News Updates